Hemogenyx Pharmaceuticals PLC University of Oxford Collaboration (9031W)
November 20 2017 - 2:00AM
UK Regulatory
TIDMHEMO
RNS Number : 9031W
Hemogenyx Pharmaceuticals PLC
20 November 2017
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
University of Oxford Collaboration
Collaboration promises to 'turbo-charge' development of blood
cancer treatments
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), a biotechnology
company developing novel therapies to transform bone marrow, or
blood stem cell, transplantation for the treatment of blood
diseases, has entered into a collaboration with the University of
Oxford to test new means of accelerating and improving the process
by which transplanted blood stem cells grow and make healthy blood
cells.
Hemogenyx will leverage the experience of researchers at the
University of Oxford in administering certain biologics to stem
cells to attempt to accelerate and improve the engraftment of
hematopoietic stem and progenitor cells in animal models.
Engraftment is the process by which blood stem cells integrate into
the bone marrow and make healthy blood. If successful, this
approach has the potential to dramatically improve the efficiency
and safety of bone marrow transplants.
Hemogenyx also will test whether this approach facilitates the
conversion of Human Post-natal Hemogenic Endothelial Cells
(Hu-PHEC), Hemogenyx's proprietary source of blood stem cells, into
fully functional, transplantable blood stem cells. Hu-PHEC generate
cancer-free, patient-matched blood stem cells and are the basis of
Hemogenyx's cell therapy product. Using Hu-PHEC, Hemogenyx intends
to revolutionize bone marrow transplants, improving the efficacy of
the therapy and potentially eliminating the need to find a matching
bone marrow donor, a problem that the majority of patients who need
allogeneic bone marrow transplants currently face.
Blood cancers affect more than 1.1 million people in the United
States each year and it is estimated that 171,500 new patients were
diagnosed with blood cancer in 2016. Currently, up to 60% of
patients who need allogeneic bone marrow transplants are unable to
find a donor match for the procedure, and, for those who do manage
to identify a donor, up to 50% of bone marrow transplants fail due
to the body's rejection of the transplant, complications from the
procedure or a relapse of the disease. Hemogenyx seeks to
fundamentally change how bone marrow transplantation is performed
and allow more people who need transplants to be able to obtain
them by eliminating the need for a donor and improving their
efficacy.
Professor Jagdeep Nanchahal at the University of Oxford, who is
leading the Oxford team in the collaboration with Hemogenyx, said:
"I'm excited to be partnering with Hemogenyx on their
ground-breaking medical research. The in-vivo tests Hemogenyx is
about to conduct have the potential to improve stem cell
engraftment for patients suffering from blood cancers."
Dr. Vladislav Sandler, CEO of Hemogenyx, said: "The
collaboration between Hemogenyx and the University of Oxford
promises to completely transform the treatment of blood cancers and
turbo-charge the development of Hemogenyx's Hu-PHEC technologies.
By pairing Oxford's established science and know-how with
Hemogenyx's advanced technologies, we are moving closer to
developing reliable products that will eventually save lives."
Enquiries:
Hemogenyx Pharmaceuticals Limited www.hemogenyx.com
Dr Vladislav Sandler, Chief Via Walbrook PR
Executive Officer & Co-Founder
Dr Robin Campbell, Chairman
Optiva Securities Ltd Tel: +44 (0)20 3137
1902
Christian Dennis
Shard Capital Partners LLP Tel: +44 (0)20 7186
9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Tel: +44 (0)20 7469
Limited 0930
Lucy Williams/Duncan Vasey
Walbrook PR Tel: +44 (0)20 7933 8780 or
hemogenyx@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE:
HEMO) headquartered in London, with its wholly owned U.S. operating
subsidiary, HemoGenyx LLC, located in its state-of-the-art research
facility in Brooklyn, New York. HemoGenyx is a preclinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapies and treatments for blood
diseases such as leukemia and lymphoma. The company's leading
technologies aim to change the way in which bone
marrow/hematopoietic stem cell (BM/HSC) transplants are performed
and improve their efficacy. HemoGenyx's two distinct and
complementary products include an immunotherapy product for patient
conditioning-the CDX bi-specific antibody-and a cell therapy
product for BM/HSC transplantation-the HuPHEC. Each of these
products holds the potential to revolutionize the way BM/HSC
transplants are being performed, offering solutions that mitigate
the dangers and limitations associated with the current standard of
care. For more information, visit www.hemogenyx.com.
About Prof. Nanchahal
Jagdeep Nanchahal is a surgeon scientist with a particular
interest in translating discoveries from the lab through to early
clinical trials.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLLFLSLSLALID
(END) Dow Jones Newswires
November 20, 2017 02:00 ET (07:00 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024